Skip to main content
SpringerLink
Log in

Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Chapter
  • First Online:
Head and Neck Cancer

Abstract

Most patients with recurrent or metastatic head and neck squamous cell cancers qualify for palliative treatment. The management of these patients includes supportive care only, mono- or multiagent chemotherapy, and more recently targeted therapies. While platinum-based combinations are superior to single-agent therapies in terms of response rate, they are more toxic and so far have not shown to lead to meaningful survival benefit. Attempts to improve on this by using other or additional cytotoxic drugs were unsuccessful in the last 30 years. It was therefore an urgent need to investigate the efficacy of novel anticancer therapies that specifically target the tumor cells in such patients. A recent randomized trial showed that adding cetuximab, an EGFR-directed monoclonal antibody, to a standard platinum-based chemotherapy regimen led to an important survival benefit. Despite the still dismal prognosis, the outcome of this latter trial has changed practice in this category of head and neck cancer patients. The next challenge will be to sort out how to incorporate the numerous targeted agents that are currently studied into the existing treatment strategies, also in consideration of an optimization of their therapeutic index.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Licitra L, Locati LD, Bossi P. Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. Ann Oncol. 2008;19 Suppl 7:vii200–3.

    Article  PubMed  Google Scholar 

  2. Vermorken JB. Medical treatment in head and neck cancer. Ann Oncol. 2005;16 Suppl 2:ii258–64.

    Article  PubMed  Google Scholar 

  3. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2644–52.

    Article  PubMed  CAS  Google Scholar 

  4. Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin Oncol. 1988;15(1):70–85.

    PubMed  CAS  Google Scholar 

  5. Amer MH, Al-Sarraf M, Vaitkevicius VK. Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer. 1979;42:2202–6.

    Article  Google Scholar 

  6. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1245–51.

    PubMed  CAS  Google Scholar 

  7. Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10(2):257–63.

    PubMed  CAS  Google Scholar 

  8. Stell PM, McCormick MS. The design of phase III palliative chemotherapy trials in head and neck cancer. Clin Otolaryngol Allied Sci. 1986;11:21–9.

    Article  PubMed  CAS  Google Scholar 

  9. Argiris A, Li Y, Forastiere A. Prognostic factors and long/term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. An analysis of two Eastern Cooperative Oncology Group randomized trials. Cancer. 2004;101:2222–9.

    Article  PubMed  Google Scholar 

  10. Leon X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol. 2005;17:418–24.

    Article  CAS  Google Scholar 

  11. Specenier P, Rasschaert M, Vroman PH, et al. Weekly docetaxel in patients with recurrent and-or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2010; Oct 8 [Epub ahead of print].

    Google Scholar 

  12. Urba SG, Forastiere AA. Systemic therapy of head and neck cancer: most effective agents, areas of promise. Oncology (Williston Park). 1989;4:79–88.

    Google Scholar 

  13. Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Al-Sarraf M. A randomized trial of cisplatin (CACP) and 5-fluorouracil (5-FU) infusion and CACP  +  5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer. 1985;56:2740–4.

    Article  PubMed  CAS  Google Scholar 

  14. Amrein PC, Weitzman SA. Treatment of squamous cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol. 1985;3:1632–9.

    PubMed  CAS  Google Scholar 

  15. Tannock IF. Chemotherapy for head and neck cancer. J Otolaryngol. 1984;13:99–104.

    PubMed  CAS  Google Scholar 

  16. Al-Sarraf M. Chemotherapy strategies in squamous cell carcinoma of the head and neck. Crit Rev Oncol Hematol. 1984;1:323–55.

    Article  PubMed  CAS  Google Scholar 

  17. Carter SK, Slavik M. Current investigational drugs of interest in the chemotherapy program of the National Cancer Institute. Natl Cancer Inst Monogr. 1977;45:101–21.

    Google Scholar 

  18. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5(6):521–6.

    PubMed  CAS  Google Scholar 

  19. Hong WK, Schaefer S, Issell B, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer. 1983;52:206–10.

    Article  PubMed  CAS  Google Scholar 

  20. Eisenberger M, Hornedo J, Silva H, et al. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1986;4:1506–9.

    PubMed  CAS  Google Scholar 

  21. Wittes RE. Chemotherapy of head and neck cancer. Otolaryngol Clin North Am. 1980;13:515–20.

    PubMed  CAS  Google Scholar 

  22. Glick JH, Zehngebot LM, Taylor SG. Chemotherapy for squamous cell carcinoma of the head and neck: a progress report. Am J Otolaryngol. 1980;1:306–23.

    Article  PubMed  CAS  Google Scholar 

  23. Airoldi M, Cortesina G, Giordano C, et al. Ifosfamide in the treatment of head and neck cancer. Oncology. 2003;65(Suppl):237–43.

    Article  Google Scholar 

  24. Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol. 2005;17:218–24.

    Article  PubMed  CAS  Google Scholar 

  25. Grau JJ, Caballero M, Verger E, Monzo M, Blanch JL. Weekly paclitaxel for platin/resistant stage IV head and neck cancer patients. Acta Otolaryngol. 2008;31:1–6.

    Article  Google Scholar 

  26. Pivot X, Raymond E, Laguerre B, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001;85:649–55.

    Article  PubMed  CAS  Google Scholar 

  27. Testolin A, Recher G, Cristoferi V, et al. Vinorelbine in pre-treated advanced head and neck squamous cell carcinoma: a phase II study. Invest New Drugs. 1994;12:213–34.

    Article  Google Scholar 

  28. Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with squamous head and neck cancer with locoregional and/or metastatic relapse after previous platinum-based treatment: final results of Spanish Head and Neck Cancer Group. J Clin Oncol. 2009;27(15S):312s. Abstract 6047.

    Google Scholar 

  29. Murphy BA. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert Opin Pharmacother. 2005;6:85–92.

    Article  PubMed  CAS  Google Scholar 

  30. Schornagel JH, Verweij J, de Mulder PH, et al. Randomized phase III trial of edetrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol. 1995;13:1649–55.

    PubMed  CAS  Google Scholar 

  31. Park S, Lee S, Park J, Cho E, Shin D, Lee J. Phase II study of oral S-1 in pretreated patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2008;26(15S):692s. Abstract 17007.

    Google Scholar 

  32. Hitt R, Amador ML, Quintela-Fandino M, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer. 2006;106:106–11.

    Article  PubMed  CAS  Google Scholar 

  33. Colevas AD, Amrein PC, Gomolin H, et al. A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. Cancer. 2001;92:326–31.

    Article  PubMed  CAS  Google Scholar 

  34. Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group study. Cancer Treat Rep. 1985;69(6):577–81.

    PubMed  CAS  Google Scholar 

  35. Vermorken JB, Catimel G, de Mulder P, et al. Randomized phase II trial of weekly methotrexate versus two schedules of three-weekly paclitaxel in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 1999;18:395a. Abstract 1527.

    Google Scholar 

  36. Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004;40(14):2071–6.

    Article  PubMed  CAS  Google Scholar 

  37. Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol. 1985;15:283–9.

    Article  PubMed  CAS  Google Scholar 

  38. De Andres L, Brunet J, Lopez-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol. 1995;13(6):1493–500.

    PubMed  Google Scholar 

  39. Eisenberger M, Krasnow S, Ellenberg S, et al. A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer. J Clin Oncol. 1989;7(9):1341–5.

    PubMed  CAS  Google Scholar 

  40. Clavel M, Cognetti F, Dodion P, et al. Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer. 1987;60(6):1173–7.

    Article  PubMed  CAS  Google Scholar 

  41. Schantz SP, Harrison LB, Forastiere AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles & practice of oncology. 6th ed. Philadelphia: Lippincott-Raven; 2001. p. 797–860.

    Google Scholar 

  42. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16(4):1325–30.

    PubMed  CAS  Google Scholar 

  43. Shin DM, Khuri FR, Glisson BS, et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer. 2001;91(7):1316–23.

    Article  PubMed  CAS  Google Scholar 

  44. Gibson MK, Li Y, Murphy B, Hussain MH, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an Intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562–7.

    Article  PubMed  CAS  Google Scholar 

  45. Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group phase II study. Cancer Invest. 2007;25(3):182–8.

    Article  PubMed  CAS  Google Scholar 

  46. Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol. 2000;23(2):128–31.

    PubMed  CAS  Google Scholar 

  47. Benasso M, Ponzanelli A, Merlano M, et al. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group. Acta Oncol. 2006;45(2):168–74.

    Article  PubMed  CAS  Google Scholar 

  48. Specenier P, Vermorken JB. Targeted therapies in head and neck cancer. Targeted Oncol. 2007;2(2):73–8.

    Article  Google Scholar 

  49. Cohen EEW. Novel therapeutic targets in squamous cell carcinoma of the head and neck. Semin Oncol. 2004;31:755–68.

    Article  PubMed  CAS  Google Scholar 

  50. Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res. 1999;5:4164–74.

    PubMed  CAS  Google Scholar 

  51. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350–6.

    PubMed  CAS  Google Scholar 

  52. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006;24:4170–6.

    Article  PubMed  CAS  Google Scholar 

  53. Eriksen JG, Steiniche T, Askaa J, et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2004;58:561–6.

    Article  PubMed  CAS  Google Scholar 

  54. Santini J, Formento JL, Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck. 1991;13:132–9.

    Article  PubMed  CAS  Google Scholar 

  55. Licitra L, Rolland F, Bokemeyer C, et al. Biomarker potential of EGFR gene copy number by FISH in the phase III EXRTREME study: platinum-based CT plus cetuximab in first-line R/M SCCHN. J Clin Oncol. 2009;27(15S):302s. Abstract 6005.

    Google Scholar 

  56. Scaltriti M, Baselga J. The epidermal growth receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–72.

    Article  PubMed  CAS  Google Scholar 

  57. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 2007;98:1275–80.

    Article  PubMed  CAS  Google Scholar 

  58. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. 2004;173:4699–707.

    PubMed  CAS  Google Scholar 

  59. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol. 2010;184:512–20.

    Article  PubMed  CAS  Google Scholar 

  60. Rapidis AD, Vermorken JB, Bourhis J. Targeted therapies in head and neck cancer: past, present and future. Rev Recent Clin Trials. 2008;3:156–66.

    Article  PubMed  CAS  Google Scholar 

  61. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 2004;64:5355–62.

    Article  PubMed  CAS  Google Scholar 

  62. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res. 2004;10:6487–501.

    Article  PubMed  CAS  Google Scholar 

  63. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5568–77.

    Article  PubMed  CAS  Google Scholar 

  64. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5578–87.

    Article  PubMed  CAS  Google Scholar 

  65. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–7.

    Article  PubMed  CAS  Google Scholar 

  66. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24(18):2866–72.

    Article  PubMed  CAS  Google Scholar 

  67. Hitt R, Irigoyen A, Nuñez J, et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck cancer group (TTCC). J Clin Oncol. 2007;25(18S):302s. Abstract 6012.

    Google Scholar 

  68. Buentzel J, de vries A, Micke O. Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer. J Clin Oncol. 2007;25(18S):318s. Abstract 6077.

    Google Scholar 

  69. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23(34):8646–54.

    Article  PubMed  Google Scholar 

  70. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.

    Article  PubMed  CAS  Google Scholar 

  71. Petrelli NJ, Winer EP, Brahmer J, et al. Clinical cancer advances 2009 major research advances in cancer treatment, prevention, and screening – a report from the American Society of Clinical Oncology. J Clin Oncol. 2009;27(35):6052–69.

    Article  PubMed  Google Scholar 

  72. Carteni G, Fiorentino R, Vecchione L, Chiurazzi B, Battista C. Panitumumab a novel drug in cancer treatment. Ann Oncol. 2007;18 Suppl 6:vi16–21.

    Article  PubMed  Google Scholar 

  73. Vermorken JB, Stöhlmacher J, Davidenko I, et al. An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM). J Clin Oncol. 2009;27(15S):313s. Abstract 6050.

    Google Scholar 

  74. Bier H, Hoffman T, Hauser U, et al. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD72000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol. 2001;47:519–24.

    Article  PubMed  CAS  Google Scholar 

  75. Arteaga ME, Ledón N, Casacó A, et al. Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab. Cancer Biol Ther. 2007;6:1390–5.

    Article  PubMed  CAS  Google Scholar 

  76. Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs. 2009;1:41–8.

    Article  PubMed  Google Scholar 

  77. Specenier P, Vermorken JB. Advances in the systemic treatment of head and neck cancers. Curr Opin Oncol. 2010;22(3):200–5.

    Article  PubMed  Google Scholar 

  78. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:1864–71.

    Article  PubMed  CAS  Google Scholar 

  79. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2006;24(18S):297s. Abstract 5568.

    Google Scholar 

  80. Cohen EE, Halpern AB, Kasza K, et al. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009;45:155–60.

    Article  Google Scholar 

  81. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 2007;25:2178–83.

    Article  PubMed  CAS  Google Scholar 

  82. Belon J, Irigoyen A, Rodriguez I, et al. Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck. J Clin Oncol. 2005;23(16S):515s. Abstract 5563.

    Google Scholar 

  83. Kim ES, Kies MS, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. J Clin Oncol. 2007;25(18S):302s. Abstract 5521.

    Google Scholar 

  84. Argiris A, Ghebremichael M, Gilbert J, et al. A phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol. 2009;27(15S):303s. Abstract 6011.

    Google Scholar 

  85. Gillison ML, Glisson BS, O’Leary E, et al. Phase II trial of trastuzumab (T), paclitaxel (P), and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): response by tumor EGFR and HER2/neu status. J Clin Oncol. 2006;24(18S):282s. Abstract 5511.

    Google Scholar 

  86. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131:624–30.

    Article  PubMed  CAS  Google Scholar 

  87. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11:1434–40.

    Article  PubMed  CAS  Google Scholar 

  88. Seiwert TY, Haraf DJ, Cohen EEW, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008;26:1732–41.

    Article  PubMed  CAS  Google Scholar 

  89. Karamouzis MV, Friedland D, Johnson R, Rajasenan K, Branstetter B, Argiris A. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): an interim analysis. J Clin Oncol. 2007;25(18S):311s. Abstract 6049.

    Google Scholar 

  90. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009;10:247–57.

    Article  PubMed  CAS  Google Scholar 

  91. Gibson MK, Kies M, Kim S, et al. Cetuximab and bevacizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an updated report. J Clin Oncol. 2009;27(15S):313s. Abstract 6049.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem, 2650, Belgium

    Jan B. Vermorken

Authors
  1. Jan B. Vermorken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan B. Vermorken .

Editor information

Editors and Affiliations

  1. , Dept of Radio-Oncology, Genolier Swiss Medical Network, 4 Route du Muids, Genolier, CH-1272, Switzerland

    Jacques Bernier

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Vermorken, J.B. (2011). Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. In: Bernier, J. (eds) Head and Neck Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9464-6_47

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9464-6_47

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-9463-9

  • Online ISBN: 978-1-4419-9464-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation